Dongcheng Biochemicals subsidiary seeks HKEX main board listing

Yantai Dongcheng Biochemicals Group Co., Ltd. announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. ("Lannacheng"), is seeking a listing on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX). The company's board of directors and shareholders approved the spin-off in August and September 2025, respectively.

On September 29, 2025, Lannacheng submitted its application materials for an initial public offering and listing on the HKEX Main Board. These application materials are published on the HKEX website in draft form, subject to updates and revisions.

The spin-off and listing process requires approval from the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the HKEX. Investors are cautioned that the timing and ultimate success of these approvals are uncertain, and the company will continue to disclose information as the process unfolds.